{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"RNA test identifies large B-cell lymphoma subtypes: Lisa Rimsza, M.D.","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/00d1ec8f\"></iframe>","width":"100%","height":180,"duration":653,"description":"Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately define subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy for these cancers.\nSpeaker 2: (00:32)\n Could you provide a brief background about yourself?\n \nSpeaker 2: (01:12)\n Would you give us an overview of the PM3CX test?\n \nSpeaker 2: (03:02)\n Which patients should have this testing? \n \nSpeaker 2: (05:14)\n Is this test qualitative and RNA?\n \nSpeaker 2: (06:35)\n After determining if it's primary mediastinal large B-cell lymphoma or diffuse large B-cell lymphoma, does the test identify the cell of origin?\n \nSpeaker 2: (08:09)\n For patients diagnosed with diffuse large B-cell lymphoma, what are the treatment recommendations?\n \nSpeaker 2: (09:04)\nAre there any other insights about this test that you'd like to share?","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}